Business Wire

MN-CARGILL

1.2.2024 07:04:08 CET | Business Wire | Press release

Share
Cargill becomes first global edible oils supplier to meet World Health Organization’s best practice on eliminating industrially produced trans-fatty acids

As of Jan. 1, 2024, every Cargill food customer, no matter where they are in the world, can be confident that the company’s fats and oils comply with the World Health Organization’s (WHO) recommended maximum tolerance level for industrially produced trans-fatty acids (iTFA) in fats and oils. Cargill has achieved this milestone by becoming the first global supplier whose entire worldwide edible oils portfolio meets the WHO’s best practice standard on iTFAs, limiting iTFA content to no more than two grams per 100 grams of fats/oils, including in countries where there is currently no legislative mandate.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240131485973/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Cargill has helped hundreds of customers reformulate and innovate nutritious and tasty products that meet WHO standards on iTFA (Photo: Business Wire)

While Cargill announced its commitment to removing iTFAs from its fats and oils portfolio in December 2021, the achievement reflects decades of work. The company’s iTFA journey spans more than a quarter century including early innovation, millions of dollars of investments in capital expenses and resources, and thousands of R&D hours. Along the way, Cargill has helped more than 400 customers create nutritious and tasty products that contribute to happier, healthier lives, removing more than 1.5 billion pounds of products containing iTFAs from the global food supply.

“We’re pleased to see Cargill’s continued commitment to reduce industrially produced trans fats in all their oils, recently achieving their goal to align with the World Health Organization’s recommended standards,” says René Lammers, PepsiCo’s chief science officer. “This move aligns with PepsiCo’s successful reduction of iTFAs in our foods to meet this same standard, and we encourage our fellow industry partners to join us in this important initiative to evolve our food and beverage portfolio to be better for the planet and people.”

In the past two years alone, Cargill has invested an additional $8.5 million to upgrade facilities to reduce the amount of transfat produced during oil processing, while working closely with more than 100 additional customers in two dozen countries to reformulate new product solutions that meet their needs.

iTFAs are most often formed through the partial hydrogenation of vegetable oils (PHOs) but can also be created by high thermal treatment during edible oil refining. In 2018, the WHO called for the global elimination of iTFAs by 2023, noting that trans fats intake greater than 1 percent of total energy intake is associated with coronary heart disease events and mortality.

"We’re extremely proud that we’ve met our commitment and helped fulfill our purpose -- nourishing the world in a safe, responsible and sustainable way,” said Natasha Orlova, Cargill vice president for edible oils and managing director for North America. “Taking this industry-leading step, even in countries without current iTFA legislation, helps ensure consistency in their supply chain for larger food manufacturers, while offering Cargill’s breadth of innovation and experience to smaller manufacturers.”

To ensure compliance, Cargill has added iTFAs to its larger food safety and quality assurance program. This systems-based approach includes multiple layers of monitoring, compliance and auditing.

In its latest progress report, the WHO noted that policies limiting the use of iTFAs have only been implemented in 60 of the world’s countries, covering approximately 43% of the global population. This leaves the majority of the world’s consumers at risk for continued iTFA consumption. The report called on major suppliers of oils and fats to “follow the pioneering effort of Cargill to remove industrially produced TFA from the products that are sold to food manufacturers globally.”1

“We are the first and only global edible oil supplier to commit to and meet the WHO standards consistently and across the board for our full global portfolio, and while we are understandably proud of this milestone, the WHO report highlights that much work remains,” Orlova said. “We have proven it is not only feasible to meet the iTFA recommendations while being mindful of saturated fat levels, but it can also be done without discernably changing the taste or texture of consumers’ favorite foods. We call upon other industry players to follow our lead and remove iTFAs from all their products, too.”

Cargill has also taken steps to help advance industry-wide reformulation during the past two years, particularly in countries that did not have iTFA regulation at the time of the company’s commitment. Among its actions, in Pakistan, Cargill partnered with the Sustainable Development Policy Institute on a public awareness campaign. In Malaysia and Mexico, the company interacted with industry, academic and government stakeholders to raise awareness of WHO best practices, while sharing experiences and expertise in iTFA reformulation.

1 “Countdown to 2023: WHO Report on Global Trans Fat Elimination,” World Health Organization, 2022. Download at: https://www.who.int/publications/i/item/9789240067233

About Cargill

Cargill is committed to providing food, ingredients, agricultural solutions, and industrial products to nourish the world in a safe, responsible, and sustainable way. Sitting at the heart of the supply chain, we partner with farmers and customers to source, make and deliver products that are vital for living.

Our 160,000 team members innovate with purpose, providing customers with life’s essentials so businesses can grow, communities prosper, and consumers live well. With 159 years of experience as a family company, we look ahead while remaining true to our values. We put people first. We reach higher. We do the right thing—today and for generations to come. For more information, visit Cargill.com and our News Center.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240131485973/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme

Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release

Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting

Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release

On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-

Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release

Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac

The Estée Lauder Companies Appoints Madeleine Boyd as Senior Vice President, Global Brand Communications16.7.2026 22:22:00 CEST | Press release

The Estée Lauder Companies Inc. (NYSE: EL) today announced the appointment of Madeleine Boyd as Senior Vice President, Global Brand Communications, effective July 20, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716738393/en/ Photo by Esteban La Tessa As part of the company’s continued efforts to strengthen how its brands better connect with consumers, Ms. Boyd will establish and lead a newly integrated Global Brand Communications team. In this role, she will ensure the company’s diverse portfolio is anchored by a cohesive enterprise communications strategy, while accelerating bold, consumer-first storytelling that drives earned media, cultural relevance, and brand desirability. She will also strengthen creator engagement, helping the company’s brands gain attention where culture is being shaped. Ms. Boyd brings extensive experience spanning brand strategy, communications, consumer engagement, and cultural insight

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye